Topiramate is an antiepileptic drug with anti-seizure properties around the board. It has been shown to be successful in the treatment of both partial and generalised seizures. Topiramate's effectiveness in epilepsy syndromes such as West syndrome, myoclonic-astatic epilepsy and Dravet syndrome, as well as refractory status epilepticus, has been demonstrated. Topiramate may also be used as a supplement to other treatments for Lennox-Gastaut syndrome. However, there are few studies on Topiramate's longterm efficacy, especially in children, that have lasted longer than 24 months. In this open-label, retrospective research, we looked at the safety and long-term efficacy of topiramate in a group of children with drug-resistant epilepsy for more than 24 months. The Fisher's exact test and the Chi-square test for non parametric data were used for statistical evaluation. Apart from intermittent minor side effects such as hyperactivity in ten percent of population, anorexia in four percent, sleeplessness in four percent, sedation in ten percent, hypohidrosis in eight percent, and vomiting symptoms in two percent, no significant systemic side effects were observed; none of the participants stopped TPM due to its side effects. Before and after the analysis, all haematological, hepatic, and renal parameters were normal.